CN108883131B - 调节髓源性抑制细胞的炎性小体活化用于治疗GvHD或肿瘤 - Google Patents

调节髓源性抑制细胞的炎性小体活化用于治疗GvHD或肿瘤 Download PDF

Info

Publication number
CN108883131B
CN108883131B CN201680046264.8A CN201680046264A CN108883131B CN 108883131 B CN108883131 B CN 108883131B CN 201680046264 A CN201680046264 A CN 201680046264A CN 108883131 B CN108883131 B CN 108883131B
Authority
CN
China
Prior art keywords
mdsc
mdscs
gvhd
inflammasome
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680046264.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN108883131A (zh
Inventor
B·R·布莱扎
B·H·科恩
P·J·默里
J·P·Y·廷
R·蔡瑟
J·S·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Ludwigs Universitaet Freiburg
University of North Carolina at Chapel Hill
St Jude Childrens Research Hospital
University of Minnesota System
Original Assignee
Albert Ludwigs Universitaet Freiburg
University of North Carolina at Chapel Hill
St Jude Childrens Research Hospital
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Ludwigs Universitaet Freiburg, University of North Carolina at Chapel Hill, St Jude Childrens Research Hospital, University of Minnesota System filed Critical Albert Ludwigs Universitaet Freiburg
Priority to CN202210388064.8A priority Critical patent/CN114790447A/zh
Publication of CN108883131A publication Critical patent/CN108883131A/zh
Application granted granted Critical
Publication of CN108883131B publication Critical patent/CN108883131B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
CN201680046264.8A 2015-08-06 2016-08-05 调节髓源性抑制细胞的炎性小体活化用于治疗GvHD或肿瘤 Active CN108883131B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210388064.8A CN114790447A (zh) 2015-08-06 2016-08-05 调节髓源性抑制细胞的炎性小体活化用于治疗GvHD或肿瘤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201990P 2015-08-06 2015-08-06
US62/201,990 2015-08-06
PCT/US2016/045739 WO2017024213A1 (en) 2015-08-06 2016-08-05 Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210388064.8A Division CN114790447A (zh) 2015-08-06 2016-08-05 调节髓源性抑制细胞的炎性小体活化用于治疗GvHD或肿瘤

Publications (2)

Publication Number Publication Date
CN108883131A CN108883131A (zh) 2018-11-23
CN108883131B true CN108883131B (zh) 2022-04-29

Family

ID=56686964

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680046264.8A Active CN108883131B (zh) 2015-08-06 2016-08-05 调节髓源性抑制细胞的炎性小体活化用于治疗GvHD或肿瘤
CN202210388064.8A Pending CN114790447A (zh) 2015-08-06 2016-08-05 调节髓源性抑制细胞的炎性小体活化用于治疗GvHD或肿瘤

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210388064.8A Pending CN114790447A (zh) 2015-08-06 2016-08-05 调节髓源性抑制细胞的炎性小体活化用于治疗GvHD或肿瘤

Country Status (9)

Country Link
US (2) US10894061B2 (enExample)
EP (3) EP3682889B1 (enExample)
JP (3) JP6927499B2 (enExample)
CN (2) CN108883131B (enExample)
AU (2) AU2016303622B2 (enExample)
CA (1) CA2993806A1 (enExample)
ES (2) ES2789574T3 (enExample)
PT (1) PT3682889T (enExample)
WO (1) WO2017024213A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3682889B1 (en) * 2015-08-06 2023-02-01 Regents of the University of Minnesota Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
FR3100715B1 (fr) * 2019-09-12 2023-09-29 Francais Du Sang Ets Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte
WO2022216615A1 (en) * 2021-04-05 2022-10-13 Rhode Island Hospital Compositions and methods for the prevention or treatment of rheumatoid arthritis
CN113707223A (zh) * 2021-04-21 2021-11-26 吴安华 一种预测肿瘤炎性小体活性状态及治疗敏感性的基因集系统及方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062990A1 (en) * 2008-11-26 2010-06-03 Mount Sinai School Of Medicine Of New York University In vitro generation of myeloid derived suppressor cells
CN112646777A (zh) * 2020-12-31 2021-04-13 广州医科大学 一种扩增髓系来源的抑制性细胞的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136973A1 (en) 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
EP2300000A1 (en) 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
US8951529B2 (en) 2009-12-22 2015-02-10 Icahn School Of Medicine At Mount Sinai Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases
US20140377278A1 (en) 2012-01-10 2014-12-25 Yale University Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders
AR095882A1 (es) * 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
JP6359013B2 (ja) 2013-07-29 2018-07-18 国立大学法人 鹿児島大学 １，５−ｄ−アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬
LT3240801T (lt) * 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Kombinuota navikų imunoterapija
JP6959865B2 (ja) * 2015-01-21 2021-11-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ガイドとして自身のカルレティキュリンを使用して癌細胞を食べるマクロファージ
EP3682889B1 (en) * 2015-08-06 2023-02-01 Regents of the University of Minnesota Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
KR102599839B1 (ko) 2015-11-13 2023-11-09 큐에프 테크놀로지스 에이에스 물을 모으기 위한 장치 및 방법
GB201721185D0 (en) * 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062990A1 (en) * 2008-11-26 2010-06-03 Mount Sinai School Of Medicine Of New York University In vitro generation of myeloid derived suppressor cells
CN112646777A (zh) * 2020-12-31 2021-04-13 广州医科大学 一种扩增髓系来源的抑制性细胞的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"The Nlrp3 inflammasome regulates acute graft-versus-host disease;Dragana Jankovic等;《Journal of Experimental Medicine》;20130923;第210卷(第10期);第1900页右栏第2段 *

Also Published As

Publication number Publication date
EP3331538B1 (en) 2020-03-11
EP4218776A3 (en) 2024-02-28
EP4218776A2 (en) 2023-08-02
WO2017024213A1 (en) 2017-02-09
AU2016303622B2 (en) 2022-07-07
PT3682889T (pt) 2023-03-09
US12234480B2 (en) 2025-02-25
CN108883131A (zh) 2018-11-23
ES2939534T3 (es) 2023-04-24
ES2789574T3 (es) 2020-10-26
CN114790447A (zh) 2022-07-26
AU2016303622A8 (en) 2018-05-31
CA2993806A1 (en) 2017-02-09
JP2018536620A (ja) 2018-12-13
HK1256917A1 (en) 2019-10-04
US20180214483A1 (en) 2018-08-02
EP3682889B1 (en) 2023-02-01
JP7235259B2 (ja) 2023-03-08
US20210128612A1 (en) 2021-05-06
JP2023053338A (ja) 2023-04-12
EP3682889A1 (en) 2020-07-22
EP3331538A1 (en) 2018-06-13
JP6927499B2 (ja) 2021-09-01
AU2016303622A1 (en) 2018-02-22
AU2022228188A1 (en) 2022-09-29
JP2021167345A (ja) 2021-10-21
US10894061B2 (en) 2021-01-19

Similar Documents

Publication Publication Date Title
Branisteanu et al. Update on the etiopathogenesis of psoriasis
Perrot et al. TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-γ in response to double-stranded RNA
Nestle et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
JP7235259B2 (ja) Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節
Pavlovic et al. MAIT cells display a specific response to type 1 IFN underlying the adjuvant effect of TLR7/8 ligands
JP2024091728A (ja) Ｔ細胞の拡張及び活性化の方法
HK40077184A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
Hsu et al. The effects of anti-histone H1 antibody on immune cells responsible for rejection reaction
HK1263409B (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
HK1263409A1 (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
HK40100442A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
HK40023269B (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
HK40023269A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
HK1256917B (en) Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor
Shalova et al. Monocytes and macrophages
Fu The Transcriptional Regulation and Function of IL-9 in Allergic Lung Inflammation and Tumor Growth
Alqahtani Development of autologous macrophage-encapsulated gellan fluid gel for the prevention of blindness from ocular surface scarring
Joachim Bacterial-Derived Metabolites in the Context of Immune Checkpoint Inhibitor Cancer Therapy
Minns Innate modifiers of T cell behaviour during inflammatory disease
Martini Compartmentalisation of the immune response in human skin: cross-talk between dendritic cells and T cells in healthy conditions and in psoriasis
Park YongMean et al. Eosinophil survival and apoptosis in health and disease.
Haridas Effect of EMAPII on dendritic cells
Yamaoka et al. WS/PP-024b-11 Spatiotemporal regulation of heat shock protein 90-chaperoned self-DNA and CpG-oligodeoxynucleotide for type-I interferon induction via targeting to static early endosome Y. Tamura, K. Saito, K. Okuya, T. Torigoe, N. Sato. Sapporo Medical University School of Medicine, Sapporo, Japan
Weber et al. The purinergic receptor P2X7 is a crucial inducer of inflammation in contact hypersensitivity: P104 (V08)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1263409

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant